

Reviewer #1:

1) In Treatment section, the units of chemotherapy should be stated as "mg/m<sup>2</sup>" and "area under the curve, 5 mg min/mL", instead of "mg". The dosing schedule and duration of one cycle should also be described.

Answer: This has been modified in accordance with your comments, as detailed in the treatment section.

2) When using the words "N-SCLC" and "P-SCLC" for the first time, they should not be abbreviated.

Answer: This has been modified in accordance with your comments, and "N-SCLC" and "P-SCLC" are not abbreviated when they first appear.

3) The authors detailed previous reports of this rare disease. A table summarizing them would be helpful for better understanding.

Answer: The literature has been sorted into Table 1 according to your comments.

Reviewer #2:

1. Eliminate multiple duplicate content. After that please check the manuscript thoroughly and eliminate all or reduce duplicate content. For instance, "Combined small cell lung cancer is a special subtype of small cell lung cancer that is relatively rare, aggressive, and prone to early metastasis and has a poor prognosis", it repeated too often.

Answer: The duplicate content has been deleted according to your comments.

2. Eliminate multiple references. Eliminate the lumps in the manuscript. This should be done by characterizing each reference individually. This can be done by mentioning 1 or 2 phrases per reference to show how it is different from the others and why it deserves mentioning.

Answer: This section was further revised and refined according to your suggestions, as detailed in the manuscript.

3. Refer to the reference format of the journal. Determine the document format according to the author guidelines. The number of authors mentioned in the references should be consistent.

Answer: This journal requires references to list all authors, so the number of authors is inconsistent.

4. Prognosis of this case should be included. In addition to the obvious reduction of pulmonary lesions, other aspects of the case, such as survival period, can also be followed up.

Answer: The prognosis of patients was supplemented, which was specifically modified as follows: "The lung lesion was significantly reduced after 6 cycles of immunotherapy combined with chemotherapy (Figure 1B-E, G-J), and the comprehensive efficacy evaluation was a partial response. So far, the patient has a PFS of 4.5 months. We will keep an eye on this in the future".

5. Reorganize the full text to strengthen the logic. Check the full text carefully, the logic of the article should be modified to make it more readable.

Answer: According to your suggestions, the logic of the full text has been further modified and improved. For details, please read the full text.